FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma By Ogkologos - February 25, 2026 10 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe Updated Oncogene-Addicted mNSCLC Living Guideline v1.3 Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma MOST POPULAR Smoking among young adults increased by 25% during first lockdown August 25, 2021 Strategy May Prevent Tumor Resistance to Targeted Cancer Therapies March 17, 2023 Development of T-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy July 22, 2024 Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer August 9, 2022 Load more HOT NEWS The Unique Challenges Teenagers and Young Adults With Cancer Face: An... Health-Conscious Coffee Drinkers Are Ditching the Cream and Sugar in Favor... Veteran and His Loyal Dog Pass Away Within Hours Of Each... The Benefits of Yoga During Cancer and How to Get Started
